ESR1 and breast carcinoma: The first-in-human phase I/II study (ClinicalTrials.gov ID: NCT04072952, Arvinas Estrogen Receptor, Inc., Pfizer) revealed the clinical safety and activity of vepdegestrant monotherapy in breast cancer patients.